Teva Pharmaceutical Industries Ltd. TEVA today presented data from a
sub-analysis of a Phase III clinical trial of Milprosa™ (progesterone) vaginal
ring, an investigational, once-weekly therapy for luteal phase support in
women undergoing in vitro fertilization (IVF). The results were presented at
the 61^st Annual Meeting of the Pacific Coast Reproductive Society (PCRS).
These data are from a sub-analysis of a Phase III, single-blinded, randomized
study of 1,297 women that compared the efficacy and safety of once-weekly
Milprosa™ to daily 8 percent progesterone vaginal gel for luteal phase support
in IVF. The data reported the mean number of embryos transferred and
demonstrated comparable multiple pregnancy rates (twins or triplets) and
multiple live births for each treatment.
“This data analysis provides further evidence that Milprosa™ is comparable to
progesterone vaginal gel in efficacy, regardless of how many embryos are
transferred,” said Vicki Schnell, M.D., FACOG, founder and medical director of
the Center of Reproductive Medicine in Webster, Texas. “Additionally, these
data are consistent with the recent trend towards the transfer of fewer
embryos during IVF. Transferring fewer embryos is beneficial for women as it
reduces the risk of higher order gestations, which may lead to safer
pregnancies.”
The analysis also found:
* At eight weeks gestation, the overall multiple pregnancy rates were 41.3
percent among women treated with Milprosa™ and 39.7 percent among women
treated with the vaginal gel.
* At 12 weeks gestation, the overall multiple pregnancy rates were 39.3
percent and 37.8 percent for Milprosa™ and the vaginal gel, respectively.
* The overall multiple live birth rates were 38.7 percent and 36.2 percent
for Milprosa™ and the vaginal gel, respectively.
* The mean number of embryos transferred was 2.13 for both treatment groups.
* The majority of women in both treatment groups had one or two embryos
transferred (81.8% in the Milprosa™ group; 80.8% in the vaginal gel
group).
* No higher order multiple gestations beyond triplets were recorded.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in